Hvsen Biotechnology Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Weiyuan Zhang

Chief executive officer

CN¥1.2m

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	1.4yrs
Board average tenure	1.4yrs

Recent management updates

Recent updates

Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stocks Shoot Up 37% But Its P/E Still Looks Reasonable

Mar 29

CEO

Weiyuan Zhang (54 yo)

no data

Tenure

CN¥1,170,000

Compensation

Mr. Weiyuan Zhang is Chairman & GM of Hvsen Biotechnology Co., Ltd.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Weiyuan Zhang	Chairman & GM	no data	CN¥1.17m	no data
Jie Liu	Vice Chairman & Chief Scientist	1.4yrs	CN¥667.80k	no data
Kaijie Yang	Deputy GM & CFO	7.4yrs	CN¥675.30k	0.0081% CN¥ 195.6k
Zexiang Liu	Director & Assistant to the GM	no data	CN¥604.80k	no data
Jie Han	Deputy General Manager	no data	CN¥451.00k	no data
Hongxia Li	Director of Warehousing & Logistics Data and Supervisor	no data	no data	no data
Jian Zhou	Chairman of the Supervisory Board & Assistant to the GM	1.4yrs	CN¥259.60k	no data
Wenge Ding	Product & Technical Service Director and Supervisor	1.4yrs	no data	no data

1.4yrs

Average Tenure

51yo

Average Age

Experienced Management: 300871's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Weiyuan Zhang	Chairman & GM	no data	CN¥1.17m	no data
Jie Liu	Vice Chairman & Chief Scientist	1.4yrs	CN¥667.80k	no data
Zexiang Liu	Director & Assistant to the GM	1.4yrs	CN¥604.80k	no data
Hongxia Li	Director of Warehousing & Logistics Data and Supervisor	no data	no data	no data
Jian Zhou	Chairman of the Supervisory Board & Assistant to the GM	1.4yrs	CN¥259.60k	no data
Wenge Ding	Product & Technical Service Director and Supervisor	1.4yrs	no data	no data
Huobao Xie	Independent Director	no data	CN¥100.00k	no data
Zhenling Zeng	Independent Director	no data	CN¥100.00k	no data

1.4yrs

Average Tenure

54yo

Average Age

Experienced Board: 300871's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.

Hvsen Biotechnology Management

Management criteria checks 0/4

Key information

Recent management updates

Hvsen Biotechnology Co., Ltd., Annual General Meeting, May 15, 2024

Less than half of directors are independent

Hvsen Biotechnology Co., Ltd. Approves Board Appointments

Recent updates

Hvsen Biotechnology Co., Ltd. Proposes Final Cash Dividend for 2023

Hvsen Biotechnology Co., Ltd., Annual General Meeting, May 15, 2024

First quarter 2024 earnings released: CN¥0.099 loss per share (vs CN¥0.09 profit in 1Q 2023)

Investor sentiment deteriorates as stock falls 16%

Hvsen Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stocks Shoot Up 37% But Its P/E Still Looks Reasonable

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 18%

Investor sentiment deteriorates as stock falls 18%

Less than half of directors are independent

Hvsen Biotechnology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.12 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.007 (vs CN¥0.036 in 2Q 2022)

Hvsen Biotechnology Co., Ltd. Implements Cash Dividend of A Shares for 2022, Payable on 21 June 2023

Hvsen Biotechnology Co., Ltd. Approves Cash Dividend for the Year 2022

First quarter 2023 earnings released: EPS: CN¥0.09 (vs CN¥0.01 in 1Q 2022)

Hvsen Biotechnology Co., Ltd. Approves Board Appointments

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.11 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.036 (vs CN¥0.23 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.01 (vs CN¥0.38 in 1Q 2021)

Hvsen Biotechnology Co., Ltd. (SZSE:300871) announces an Equity Buyback for CNY 100 million worth of its shares.

Hvsen Biotechnology Co., Ltd. Approves Final Cash Dividend for the Year 2021, Payable on 13 April 2022

Hvsen Biotechnology Co., Ltd. Approves Cash Dividend for 2021

Investor sentiment deteriorated over the past week

Now 22% undervalued after recent price drop

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.32 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.32 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Hvsen Biotechnology Co., Ltd. Announces Final Cash Dividend for 2020, Payable on 10 May 2021

Full year 2020 earnings released: EPS CN¥1.63 (vs CN¥0.83 in FY 2019)

Hvsen Biotechnology Co., Ltd. to Report Fiscal Year 2020 Results on Mar 29, 2021

Investor sentiment improved over the past week

New 90-day low: CN¥39.16

New 90-day low: CN¥45.36

Third quarter earnings released

Market bids up stock over the past week

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age